83896-44-0
Chemical Structure
18α-Licorice-saponin H2
Synonym(s): 18α-GA; Isoglycyrrhizinic acid; 18α-Glycyrrhizic acid
- CAS No.: 83896-44-0
- Formula:C42H62O16
- Molecular Weight:822.93
InChIKey: LPLVUJXQOOQHMX-IOHDZAKGSA-N
SMILES: C[C@]12[C@@](C(C=C3[C@]2(CC[C@@]4([C@]3([H])C[C@](C)(CC4)C(O)=O)C)C)=O)([H])[C@@]5([C@@](C(C)([C@H](CC5)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(O)=O)O)O)O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O)O)O)C(O)=O)C)([H])CC1)C
Biological Activity: 18α-Glycyrrhizic acid (18α-GA; Isoglycyrrhizinic acid; 18α-Glycyrrhizic acid) is a derivative of glycyrrhizic acid with oral activity. 18α-Glycyrrhizic acid exhibits antioxidant, anti-inflammatory, hepatoprotective and cardioprotective activities. 18α-Glycyrrhizic acid protects against ethanol-induced alcoholic liver disease in rats by upregulating the expression levels of SOD, GSH, PPAR-α and CPT-1. 18α-Glycyrrhizic acid shows cytotoxicity against T lymphocytes and inhibits HIV-1 replication in these cells. 18α-Glycyrrhizic acid alleviates oxidative stress by reducing the levels of ROS, Nrf2, HO-1 and p-P65, and alleviates pyroptosis by downregulating the expression levels of NLRP3, GSDMD-N, P20 and c-IL-1β. 18α-Glycyrrhizic acid inhibits autophagy, colonic fibrosis and myocardial fibrosis, and regulates intestinal barrier integrity. 18α-Glycyrrhizic acid can be used in research related to alcoholic liver disease, HIV-1 infection, hepatotoxicity, acute liver failure, inflammatory bowel disease and myocardial fibrosis[1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
18α-Licorice-saponin H2 | 99.90% | 18α-Glycyrrhizic acid (18α-GA; Isoglycyrrhizinic acid; 18α-Glycyrrhizic acid) is a derivative of glycyrrhizic acid with oral activity. 18α-Glycyrrhizic acid exhibits antioxidant, anti-inflammatory, hepatoprotective and cardioprotective activities. 18α-Glycyrrhizic acid protects against ethanol-induced alcoholic liver disease in rats by upregulating the expression levels of SOD, GSH, PPAR-α and CPT-1. 18α-Glycyrrhizic acid shows cytotoxicity against T lymphocytes and inhibits HIV-1 replication in these cells. 18α-Glycyrrhizic acid alleviates oxidative stress by reducing the levels of ROS, Nrf2, HO-1 and p-P65, and alleviates pyroptosis by downregulating the expression levels of NLRP3, GSDMD-N, P20 and c-IL-1β. 18α-Glycyrrhizic acid inhibits autophagy, colonic fibrosis and myocardial fibrosis, and regulates intestinal barrier integrity. 18α-Glycyrrhizic acid can be used in research related to alcoholic liver disease, HIV-1 infection, hepatotoxicity, acute liver failure, inflammatory bowel disease and myocardial fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Huo X, et al. Protective Effect of Glycyrrhizic Acid on Alcoholic Liver Injury in Rats by Modulating Lipid Metabolism. Molecules. 2018 Jul 4;23(7):1623.
- [2]. Baltina LA Jr, et al. Synthesis and antiviral activity of 18α-glycyrrhizic acid and its esters. Pharm Chem J. 2010;44(6):299-302.
- [3]. Kiso Y, et al. Mechanism of antihepatotoxic activity of glycyrrhizin. I: Effect on free radical generation and lipid peroxidation. Planta Med. 1984 Aug;50(4):298-302. [Content Brief]
- [4]. Pi W, et al. Single chiral center epimerization-modulated multi-carrier-free oral hydrogel for remolding inflammatory microenvironment via PI3K/Akt/NF-κB and MAPK signaling pathways. Bioactive materials. 2026 Jan;55:623-639.
- [5]. Chen Y, et al. Magnesium Isoglycyrrhizinate Alleviates Alectinib-Induced Hepatotoxicity by Inhibiting Mitochondrial Damage-Mediated Pyroptosis. Drug design, development and therapy. 2025;19:6219-6233. [Content Brief]
- [6]. Fan Z, et al. Magnesium Isoglycyrrhizinate Ameliorates Concanavalin A-Induced Liver Injury by Inhibiting Autophagy. Frontiers in pharmacology. 2021;12:794319.
- [7]. Cui J, et al. Improvement of magnesium isoglycyrrhizinate on DSS-induced acute and chronic colitis. International immunopharmacology. 2021 Jan;90:107194.
- [8]. Ma D, et al. Inhibition of myocardial hypertrophy by magnesium isoglycyrrhizinate through the TLR4/NF-κB signaling pathway in mice. International immunopharmacology. 2018 Feb;55:237-244.
